Clinuvel compared to Imugene, page-15

Clinuvel still undervalued, even after the share price has started moving in the right direction. In some tricky global times CUV has delivered impressive performance and grown Revenue/Profit/EPS faster than pretty much any other ASX200 stock and kept costs tightly under control. CUV trading on a modest P/E for this type of stock especially when the spectacular growth underway is taken into account - in just weeks we will see more evidence of this in the quarterly cash flow statement for the September quarter which will probably be the biggest ever. The below comparison with Imugene shows how IMU is given it's valuation (which is greater than CUV) based purely on future potential as they are not even close to having a financial performance anywhere near as good as Clinuvel, which is fine for this stage of development, but would imply more risk. The big question is when will the market start to give CUV some valuation for future indications and consequentially see the SP push up towards $100 and beyond? EPP is great and CUV has a monopoly for many years to come in this space, but Stroke, DNA Repair/Skin Cancer, Vitiligo and even OTCs have the potential to make this current CUV valuation look absolutely tiny. Importantly, the drug for all those galactic indications has proven long term safety and is already FDA, EMA, TGA and Israel approved which in itself is an achievement no other peer Aussie Biotech/Healthcare company has yet obtained.

CUV: FY20-21 Revenues: $48.5 Million, FY Profit $24.7 Million, Cash $83M MARKET CAP $2.0 Billion
IMU: FY20-21 Revenues: $0.0 , FY Loss -$18.5 Million , Cash $29M MARKET CAP $2.2 Billion


All IMO DYOR